Cellectis (CLLS) Projected to Announce Quarterly Earnings on Thursday

Cellectis (NASDAQ:CLLS) is projected to post its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect Cellectis to announce earnings of ($0.18) per share and revenue of $15.61 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 13, 2026 at 8:00 AM ET.

Cellectis Stock Performance

Cellectis stock opened at $1.11 on Wednesday. The stock’s 50 day moving average price is $1.57 and its 200 day moving average price is $2.97. The firm has a market capitalization of $111.38 million, a PE ratio of -1.71 and a beta of 3.21. The company has a debt-to-equity ratio of 1.61, a quick ratio of 1.37 and a current ratio of 1.37. Cellectis has a one year low of $0.88 and a one year high of $5.45.

Wall Street Analysts Forecast Growth

CLLS has been the topic of a number of recent analyst reports. Wells Fargo & Company cut their target price on Cellectis from $4.00 to $3.00 and set an “equal weight” rating on the stock in a research report on Tuesday, September 15th. Robert W. Baird decreased their price target on shares of Cellectis from $10.00 to $8.00 and set an “outperform” rating for the company in a research report on Tuesday, September 15th. Barclays lowered shares of Cellectis from an “overweight” rating to an “underweight” rating and dropped their price target for the stock from $9.00 to $1.30 in a research note on Wednesday, September 16th. Citizens Jmp lowered shares of Cellectis from an “outperform” rating to a “market perform” rating in a research note on Tuesday, September 15th. Finally, Weiss Ratings raised shares of Cellectis from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 2nd. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $5.46.

About Cellectis

Cellectis S.A. is a biotechnology company focused on developing gene-edited cell therapies for the treatment of cancer and other serious diseases. Founded in France in 1999, the company pioneered the use of TALEN gene-editing technology to modify immune cells and develop off-the-shelf, or allogeneic, treatments. The company’s primary programs involve genetically modified T cells, including its UCART platform of allogeneic chimeric antigen receptor T-cell therapies. These products are designed to target specific cancer antigens and are being investigated in clinical studies for hematologic malignancies and other cancers.